DEA Removes Epidiolex From Controlled Substances List

The U.S. Drug Enforcement Administration has removed the CBD pharmaceutical Epidiolex from the nation’s list of controlled substances, a move that should make it easier for patients to access the medication. Epidiolex is the only medication derived directly from cannabis that has been approved by the U.S. Food and Drug Administration for use in the United States.

The drug is a flavored oral solution with cannabidiol (CBD) that reduces seizures in children with epilepsy. The medicine, which is not psychoactive, also contains less than 0.1 percent THC. Epidiolex is produced by drug manufacturer GW Pharmaceutical at its facilities in the U.K.

After Epidiolex received FDA approval in June 2018, the drug was placed on Schedule V of the Controlled Substances Act (CSA). On Monday, GW was notified by the FDA that the drug is longer subject to the CSA, a change that goes into effect immediately.

“This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act,” said GW CEO Justin Gover in a press release.  “We would like to thank DEA for confirming the non-controlled status of this medicine. Importantly, the descheduling of

Read More Here…

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Bud Digest

Scroll to Top